Miami, Florida 33136

  • HIV Infections


The purpose of this study is to study the safety and efficacy of Amprenavir/ritonavir or saquinavir/ritonavir in HIV infected patients that have failed Kaletra as their second protease inhibitor based HAART.


Inclusion: - Subject must remain on current antiretroviral therapy during screening until a new regimen is initiated. - Subject demonstrates reduced susceptibility to lopinavir. - Subject's two most recent viral loads obtained after at least 16 weeks of lopinavir/ritonavir therapy, and while still on Kaletra therapy must be at least 1,000 copies/mL. - The Kaletra regimen must be the subject's second PI containing regimen and must not contain any other PIs. - Subject is at least 18 years of age. - Subject has not been treated for an active opportunistic infection within 30 days of screening. Exclusion: - Subject has a history of active substance abuse or psychiatric illness that could preclude compliance to the protocol. - Female subject pregnant or lactating. - Use of an Investigational drug within 30 days prior to the initiation of drug dosing. - Subject is receiving systemic chemotherapy. - Subject has a history of acute or chronic pancreatitis.

Study is Available At:

Original ID:




Secondary ID:

Study Acronym:

Brief Title:

Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease Inhibitor

Official Title:

An Open Label, Phase II Study of Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra (Lopinavir/Ritonavir) as Their Second Protease Inhibitor.

Overall Status:


Study Phase:

Phase 2/Phase 3



Minimum Age:

18 Years

Maximum Age:


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:


Oversight Authority:

United States: Food and Drug Administration

Reasons Why Stopped:

Study Type:


Study Design:

Allocation: Non-Randomized, Endpoint Classificati

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:

Overall Contact Information

Official Name:Eugene Sun, M.D.
Study Chair
Divisional Vice President, Infectious Diseases and Virology Development

Study Dates

Start Date:April 2001
Verification Date:July 2006
Last Changed Date:July 27, 2006
First Received Date:May 31, 2002

Study Outcomes

Outcome Type:Primary Outcome
Measure:Proportion of subjects with plasma HIV RNA levels below the limit of quantification (400 copies/mL) at week 24 and the time until loss of virologic response through week 48
Safety Issues:False

Study Interventions

Intervention Type:Drug
Intervention Type:Drug

Study Arms

There are no available Study Arms

Study Agencies

Agency Class:Industry
Agency Type:Lead Sponsor
Agency Name:Abbott

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source:

Date Processed: March 30, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.